TNF Pharmaceuticals Changes Fiscal Year End
Ticker: QCLS · Form: 8-K · Filed: Jul 26, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Jul 26, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: fiscal-year-change, reporting, company-name-change
TL;DR
TNF Pharma just changed its fiscal year end to Dec 31. Big deal for reporting.
AI Summary
On July 22, 2024, TNF Pharmaceuticals, Inc. filed an 8-K report detailing a change in its fiscal year end to December 31st, previously it was not explicitly stated but implied to be different. This filing also includes information regarding Regulation FD disclosure and financial statements, with exhibits filed on July 26, 2024. The company was formerly known as MyMD Pharmaceuticals, Inc. until April 20, 2021.
Why It Matters
This change in fiscal year end can impact financial reporting timelines and investor analysis of the company's performance over consistent periods.
Risk Assessment
Risk Level: low — The filing primarily concerns administrative changes to the company's fiscal reporting, with no immediate financial or operational risks indicated.
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Registrant
- July 22, 2024 (date) — Earliest event reported
- December 31 (date) — New fiscal year end
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- April 20, 2021 (date) — Date of name change from MyMD Pharmaceuticals, Inc.
FAQ
What is the new fiscal year end for TNF Pharmaceuticals, Inc.?
The new fiscal year end for TNF Pharmaceuticals, Inc. is December 31.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 22, 2024.
What was TNF Pharmaceuticals, Inc. formerly known as?
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc.
When did the company change its name from MyMD Pharmaceuticals, Inc.?
The company changed its name from MyMD Pharmaceuticals, Inc. on April 20, 2021.
What other information is included in this 8-K filing besides the fiscal year change?
This 8-K filing also includes information regarding Regulation FD disclosure and financial statements, with exhibits filed on July 26, 2024.
Filing Stats: 804 words · 3 min read · ~3 pages · Grade level 9.9 · Accepted 2024-07-26 16:05:14
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TNFA The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex3-1.htm (EX-3.1) — 14KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-2.htm (EX-99.2) — 13KB
- 0001493152-24-029227.txt ( ) — 270KB
- tnfa-20240722.xsd (EX-101.SCH) — 3KB
- tnfa-20240722_lab.xml (EX-101.LAB) — 34KB
- tnfa-20240722_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 3.1 Certificate of Amendment of Certificate of Incorporation of TNF Pharmaceuticals, Inc. 99.1 Press Release, dated July 22, 2024. 99.2 Press Release, dated July 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TNF PHARMACEUTICALS, INC. Date: July 26, 2024 By: /s/ Joshua Silverman Name: Joshua Silverman Title: Director